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1. Introduction
Amyloidosis is defined as an insoluble protein fibril that is deposited, mainly, in the extracel‐
lular spaces of organs and tissues as a result of a sequence of changes in protein folding.
Precursor proteins change their conformation that forms amyloid fibrils, then deposited
amyloid induce organ damage with disease specific conditions.
To date, there are 27 types of amyloidosis known extracellular fibril proteins in human, and
each amyloidosis is characterized amyloid protein precursor, systemic (S) or localized organ
(L), and syndrome or involved tissues [1]. In the nomenclature, dialysis-related amyloidosis
(DRA) is defined as β2-microglobulin-related (Aβ2M) amyloid which precursor protein is β2-
microglobulin (β2-m). It is associated to dialysis, a kidney replacement therapy, and deposits
in systemic (S), mainly joint tissues [1].
Long-term dialysis treatment for end-stage kidney disease often induces the Aβ2-m amyloid
deposition in mainly osteoarticular tissues that induces various disorders, such as carpal
tunnel syndrome (CTS), destructive spondyloarthropathy (DSA), and cystic bone lesions as
well as in systemic organs such as heart and gastrointestinal tract when disease advances.
Several biomolecules including β2-m as well as clinical risk factors are thought to relate with
Aβ2M amyloidogenesis (Figure 1). Recent progress of dialysis therapy has improved survival
of dialysis patients, however, older age and long-term dialysis treatment may increase the
onset and acceleration of DRA. In this article, we described about DRA focused on pathogen‐
esis, clinical manifestations and treatment, and showed DRA is still one of serious complica‐
tions for patients undergoing long-term dialysis treatment.
© 2013 Yamamoto et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Figure 1. Pathogenesis of dialysis-related amyloidosis (DRA). DRA is induced not only accumulation of β2-microglobu‐
lin but also several biomolecules and clinical risk factors.
2. Pathogenesis of dialysis-related amyloidosis
2.1. β2-microglobulin
β2-m is a polypeptide of 99 residues that has a molecular weight of 11.8 kDa. It forms the beta
chain of the human leukocyte antigen (HLA) class I molecule and has a well-known β-
sandwich structure that involves a 7-strand β-pleated structure stabilized with a single
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disulphide bond (Cys25-Cys80). β2-m changes the conformation under various in vivo or in
vitro conditions, such as acidic pH [2], 2,2,2-trifluoroethanol (TFE) [3], sodium dodecyl sulfate
(SDS) [4], lysophospholipids [5], non-esterified fatty acids [6], heating [7] and agitation [8].
Proper dose of those molecules induce conformational intermediate that is required for Aβ2M
amyloid fibril formation/extension (see below section).
2.2. Retention of conformational intermediate-β2-m
β2-m is a component of MHC class I molecules, which are present on all nucleated cells. Most
β2-m is normally eliminated by the kidney via glomerular filtration and subsequent tubular
catabolism with Megalin [9]. Thus, severe kidney damage induces the retention of β2-m in
serum due to impaired excretion from the kidney.
Some clinical studies have attempted to identify the conformational intermediate form of
circulating β2-m. Capillary electrophoresis reveals that patients undergoing hemodialysis due
to end-stage kidney disease, but not healthy control subjects, have the conformational
intermediate form of β2-m in serum [10]. The level of predialysis serum β2-m intermediate was
2.7±1.4 mg/L and native β2-m was 29.4±6.8 mg/L in 31 hemodialysis patients. Hemodialysis
using a polymethylmethacrylate and online hemodiafiltration with a polysulfone membrane
decreased the level of the native form, while any change in the intermediate form was variable
[10]. These results suggest that intermediate β2-m is increased in hemodialysis patients and is
difficult to remove with dialysis treatment. It may suggest that the intermediate form is
immobilized in the extracellular space where Aβ2-m amyloid has a marked affinity for joint
tissues (cartilage, capsule, and synovium). In addition, immunoaffinity–liquid chromatogra‐
phy–mass spectrometry analysis and immunoassay revealed the generation of lysine-58–
cleaved and truncated β2-m (ΔK58-β2-m), which was found in serum from 20–40% HD patients
but not in serum from control subjects [11]. However, this truncated form has not been
demonstrated in the tissue containing Aβ2-m amyloid [12]. It is not certain whether the
conformational intermediate or the truncated form of β2-m has a critical role of onset/progress
of DRA, and future studies will be needed to understand the pathogenesis for Aβ2-m amyloid
fibrils formation/extension.
2.3. Aβ2-m amyloid fibril formation and extension
A nucleation-dependent polymerization model explains the general mechanisms of amyloid
fibril formation in vitro, in various types of amyloidosis [13-18]. This model consists of two
phases, i.e., nucleation and extension phases. Nucleus formation requires a series of association
steps of monomers, which are thermodynamically unfavorable, representing the rate-limiting
step in amyloid fibril formation in vitro. Once the nucleus (n-mer) has been formed, further
addition of monomers to the nucleus becomes thermodynamically favorable, resulting in rapid
extension of amyloid fibrils according to a first-order kinetic model, i.e., via the consecutive
association of precursor proteins onto the ends of existing fibrils [14, 17, 18].
In the mechanism of amyloidogenesis from β2-m, natively folded proteins, partial unfolding
of protein is prerequisite to its assembly into amyloid fibrils [3, 13, 19, 20]. The extension of
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Aβ2M amyloid fibrils, as well as the formation of the fibrils from β2-m are greatly dependent
on the pH of the reaction mixture, with the optimum pH around 2.0-3.0 [13, 14]. At pH 2.5,
where the extension of Aβ2M amyloid fibrils is optimum, β2-m loses much of the secondary
and tertiary structures observed at pH 7.5 [13, 19]. Aβ2M amyloid fibrils readily depolymerize
into monomeric β2-m at a neutral pH [19], however, low concentration of TFE [3] and sub-
micellar concentration of SDS [4] induced Aβ2M amyloid fibrils extension with changing
conformation of β2-m monomer and inhibiting depolymerization of amyloid fibrils at a neutral
pH in vitro (Figure 2). While TFE and SDS are organic compounds, several biomolecules could
induce Aβ2M amyloidogenesis in vivo, such as apolipoprotein E, proteoglycans, glicosami‐
noglycans, type1 collagen, non-esterified fatty acid, and lysophospholipids. [4-6, 21, 22]. For
example, some lysophospholipids, especially lysophosphatidic acid (LPA) induces both
Figure 2. β2-microglobulin-related (Aβ2M) amyloid fibril extension in vitro. Sub-micellar concentration of sodium do‐
decyl sulfate (SDS) induces Aβ2M amyloid fibrils extension at a neutral pH while micellar concentration induces amy‐
loid fibril depolimerization in vitro. The amount of extended fibrils is measured by Thioflavin T (A), and observed by
electron microscopy (B). Bar shows 250 nm.
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amyloid fibril formation and extension at a neutral pH [5]. The mechanism of amyloidogenesis
is due to make β2-m monomer into partially unfolding the compact structure as well as
stabilizing the extended fibrils in vitro. Clinically, plasma LPA concentration is higher in
patients undergoing hemodialysis treatment as compare to healthy subjects [5]. It’s unclear
the local concentration of lysophospholipids in the lesion that Aβ2M amyloid deposits, it may
be reasonable to consider the reaction between β2-m and lysophospholipids that are increased
in chronic kidney disease (CKD) undergoing dialysis treatment. Joint tissues that Aβ2M
amyloid deposits at early stage in dialysis patients, contains many kinds of glycosaminogly‐
cans and proteoglycans. Depolymerization of Aβ2M amyloid fibrils at a neutral pH in vitro
was inhibited dose-dependently by the presence of some glycosaminoglycans (heparin,
dermatan sulfate or heparin sulfate) or proteoglycans (biglycan, decorin or keratan sulfate
proteoglycan) [21]. In addition, some glycosaminoglycans, especially heparin, enhanced the
Aβ2M amyloid fibril extension induced by low concentration of TFE at a neutral pH [3]. These
results suggest that some glycosaminoglycans and proteoglycans stabilize extended Aβ2M
amyloid fibrils possibly by binding directly to the surface of the fibrils in vivo. Heparin is
widely used for the hemodialysis treatment as an anticoagulant. Although no significant
difference in the prevalence of Aβ2M amyloidosis was found between continuous ambulatory
peritoneal dialysis patients and hemodialysis patients carefully matched for time on dialysis
and age at the onset of dialysis [23], our study may suggest that heparin could exert a subtle
effect for the development of Aβ2M amyloidosis under some clinical conditions.
Those molecules are picked up from the results of in vitro amyloid fibril formation, extension,
and depolymerization, and further studies will be needed to analyze the histological relation‐
ship between those biomolecules and Aβ2M amyloid in the lesion.
2.4. Progress of bone disease after deposition of amyloid fibrils
It is not clearly understood the progress of bone disease after deposition of amyloid fibrils.
Deposited amyloidosis induces compression that induced CTS and joint arthropathy. Also
amyloid deposition induces local osteolysis that induced bone cysts and DSA. The progress
through synovial inflammation and subsequent osteoclastogenesis and/or osteoclast activa‐
tion through three possible pathways: (i) indirect action of inflammatory cytokines through
the expression in osteoblasts of receptor activator of nuclear factor-κB ligand/osteoprotegerin
ligand (RANKL/OPGL), (ii) direct action of inflammatory cytokines, and (iii) RANKL/OPGL
expression in inflammatory cells.
3. Clinical manifestations
3.1. Serum β2-m levels in patients undergoing dialysis treatment
Advanced CKD induces the serum level of β2-m to elevate due to the impaired metabolism
and excretion in the kidney. The average serum concentration levels of β2-m in patients
undergoing dialysis is significantly higher compared to those in normal subjects (25–45 vs. 1–
2 mg/L) [10, 24-27]. It is clearly understood that the impairment of metabolism in the kidney
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is the main cause of fluid retention in HD patients; however, it is not clear whether the
production of β2-m is increased with CKD and/or dialysis treatment. However, a study shows
that the amount of β2-m on the surface of granulocytes, lymphocytes and monocytes in
hemodialysis patients is higher than that in control subjects while mRNA expression of β2-m
in blood cells is no significant difference between them [28]. This result shows the possibility
that increased binding of β2-m to blood cells is one of major cause of retention of β2-m in dialysis
patients. Thus continuous higher serum levels of β2-m could induced DRA after long-term
dialysis treatment [24, 29].
3.2. Risk factors of DRA
Risk factors of DRA are (i) long-term dialysis treatment, (ii) initiation dialysis treatment in
young age, (iii) hemodialysis treatment with low purity dialysate, (iv) use of low-flux dialysis
membrane [30], while the pathogenesis of DRA with those risk factors is still incompletely
understood. Recently it has trend to use high-flux dialysis membrane and high purity dialysate
in hemodialysis treatment. However, progress of dialysis treatment as well as treatment for
other diseases makes better survival of dialysis patients and older initiation of dialysis
treatment. Thus long-term and old age dialysis patients increase, and DRA is still one of serious
complications for patients undergoing dialysis treatment.
Serum level of β2-m, precursor protein of DRA, increase in dialysis patients and is believed
most important for onset and progress of DRA. While cross sectional study shows no relation
between onset of DRA and serum level of β2-m [24], DRA may be onset after accumulation of
β2-m with long duration of dialysis treatment [29].
3.3. Clinical manifestations
Long-term dialysis treatment for end-stage kidney disease often induces the Aβ2-m amyloid
deposition in mainly osteoarticular tissues that induces various disorders, such as CTS, DSA,
and cystic bone lesions as well as in rarely systemic organs such as heart [31] and gastrointes‐
tinal tract [32] when disease is advanced. CTS is induced by the deposition of Aβ2-m amyloid
around synovium in carpal tunnel and the compression of median nerve. DSA is induced by
the deposition of Aβ2-m amyloid and the defect of bone in spine. It is radiographically
characterized by severe narrowing of the intervertebral disk space and erosions as well as cysts
of the adjacent vertebral plates. DSA lesions are mostly detected in the highly mobile areas,
such as C5–C7 and L3–L5 [33]. Cystic lesions occur in bones, such as carpal and femur that
Aβ2-m amyloid deposition is found around them. Cystic lesions as well as mineral bone
disorder associated with CKD increase the risk of bone fracture.
DRA, induce various osteo-articular disorders, is one of serious complications in patients
undergoing long-term dialysis treatment even improvement of dialysis treatment such as
dialysis membrane and dialysate [34, 35]. For example, we researched over a four year period
359 end-stage kidney disease patients undergoing dialysis treatment were admitted in our
center for the treatment of their dialysis-related complications [34]. DSA was a major cause of
hospital admission in the patients undergoing dialysis therapy for 20 years or more, and the
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rate increased along with the increasing duration of dialysis therapy. The incidence rate of
histories of surgeries for osteoarticular disorders, related to DRA was 25.0, 66.0, and 77.8 % in
20-24 years, 25-29 years, and 30 years or more after the initiation of dialysis therapy, respec‐
tively (Figure 3). In the patients undergoing dialysis therapy for 30 years or more, the incidence
rate of histories of surgeries for CTS, DSA, and joint arthropathy was 72.2%, 50.0%, and 22.2%,
respectively that indicated they had analogous histories of surgeries for various osteoarticular
disorders (Figure 4). These results indicate that the frequency and severity of osteoarticular
disorders which may be caused by DRA accelerated with the increasing duration of dialysis
therapy especially for the patients undergoing dialysis therapy for 30 years or more.
Figure 3. The incidence rate of histories of surgeries for osteo-articular disorders, related to dialysis-related amyloido‐
sis (DRA). The rate is 25.0, 66.0, and 77.8 % in 20-24 years, 25-29 years, and 30 years or more after the initiation of
dialysis therapy, respectively. In the patients undergoing dialysis therapy for 30 years or more, the rate for carpal tun‐
nel syndrome (CTS), destructive spondyloarthropathy (DSA), and joint arthropathy was 72.2%, 50.0%, and 22.2%, re‐
spectively.
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Figure 4. A case of long-term dialysis patients complicated with various osteo-articular disorders related to dialysis-
related amyloidosis (DRA). A man had end-stage kidney disease due to chronic glomerulo nephritis and received he‐
modialysis treatment for 30 years. He had various DRA-related osteo-articlular disorders, such as carpal tunnel
syndrome (CTS), joint artholopathy, and destructive spondyloartholopahty (DSA) that needed surgical treatment.
Next, we researched 102 patients undergoing dialysis treatment for 30 years or more in our
related hospitals, and their complication of osteoarticular disorders. The age at initiation of
dialysis therapy was 27.3 ± 7.7 years, and the duration of dialysis therapy was 32.3 ± 1.8 years.
The surgery for CTS was done for 80 patients (76%) in 21.6 ± 5.5 years after the initiation of
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dialysis therapy. All of those patients received the surgeries more than 2 times, furthermore,
some of them received more than 4 times for 30 years or more. The surgery for DSA was done
for 17 patients (16%) in 27.1 ± 4.7 years after initiation of dialysis treatment. There is dissociation
in the incidence of history of surgery for DSA between in our center [34] and in our related
hospitals while that for CTS was similar. The main reason may be that our center is a university
teaching hospital and severe patients are referred to our hospital. This is a major limitation,
however, it should be remembered that one of the main causes for admission was DSA in the
patients undergoing long-term dialysis therapy. Our results may suggest that DRA is one of
most serious complications in the patients undergoing dialysis therapy for 30 years or more.
Further study will be needed about the detail of DRA in the in long-term dialysis patients. In
our studies, the main factor associated with osteoarticular disorders which may be caused by
DRA was the duration of dialysis therapy despite the younger age at initiation of dialysis
therapy [34]. Other risk factors, such as dialyzer and dialysate could not be considered because
of the consistent improvements in the technologies from year to year. For example, long-term
dialysis patients had used the low-flux dialyzer for several years since initiating therapy, but
now use a high-flux dialyzer. Short-term patients however, have used the high-flux dialyzer
since the initiation of dialysis therapy.
In summary of our clinical research, the frequency and seriousness of osteoarticular disorders
which may be caused by DRA were accelerated with the duration of dialysis therapy, especially
in cases treated for 30 years or more.
4. Treatment for DRA
Main purpose of treatment for DRA is a) to prevent the deposition of Aβ2-m amyloid fibrils in
the lesions, and b) to relieve symptoms induced by Aβ2-m amyloid deposition. Remove β2-m
with dialysis treatment and suppression of systemic/local inflammation are beneficial to
prevent the deposition of Aβ2-m amyloid fibrils. Practically, it should be used biocompatible
high-flux dialysis membrane and high purity dialysate in hemodialysis treatment. In addition,
hemofiltration, hemodiafiltration, and use of β2-m adsorption column have much effect to
reduce β2-m and to improve symptoms [36]. Non-steroidal anti-inflammatory drugs or low
dose of steroid sometimes show relief of symptoms induced by Aβ2-m amyloid deposition
while use of steroid for long duration has risk to induce adverse effect, such as infection and
osteoporosis. Surgical treatments are needed when Aβ2-m amyloid deposition induces severe
osteoarticular symptoms.
4.1. Hemodialysis/hemodiafiltration
The use of high-flux dialyzer membrane leads to a reduction in the serum level of β2-m as
compared to using low-flux dialyzer membrane. In the HEMO Study [26], the predialysis
serum β2-m level was lower in the high-flux membrane group than in the low-flux membrane
group. In another study, switching of dialyzer from conventional to high-flux membrane
reduced the predialysis serum β2-m level [37]. Clinically, Küchle et al [38]examined the effect
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of polysulfone high-flux dialysis membrane in hemodialysis treatment, and showed less onset
of CTS, arthropathy and bone cysts as well as lower concentration of serum β2-m as compare
to use of low-flux dialysis membrane. The reason why high-flux membrane produces a lower
level of serum β2-m is not only that it promotes better clearance, but that it also increases the
binding of β2-m to blood cells, such as granulocytes, lymphocytes and monocytes [28]. High
purity dialysate with low endotoxin reduced serum β2-m, pentosidine, C-reactive protein, and
interleukin-6 [39] that probably accelerates Aβ2-m amyloid deposition.
Hemodiafiltration has better clearance of middle size molecules than HD and is known to
reduce the risk of progression of DRA. A recent multicenter prospective randomized study
revealed that on line HDF showed greater efficiency than HD with low-flux membrane in
reducing the basal level of β2-m [40].
4.2. HD with β2-m adsorption column
A β2-m adsorption column has been developed as a way to directly eliminate serum β2-m. This
adsorption column system is designed for direct hemoperfusion (Figure 5). Adsorption of β2-
m by this column is a result both of hydrophobic and molecular size-dependent interactions
between the ligand in the column and β2-m molecule. The effects of this column show the
reduction rate; 60.0-78.9 %, the amount of adsorption; 157-300 mg, serum β2-m after treatment;
6.8-13.5 mg/L with single treatment [41-43].
Figure 5. A schematic representation of hemodialysis treatment with β2-microglobulin (β2-m) adsorption column. The
β2-m adsorption column is placed in series with the dialyzer, with blood flowing through the column first.
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According to a prospective multicenter study, a β2-m adsorption column that was placed in
series with a polysulfone dialyzer increased serum β2-m reduction in patients undergoing
hemodialysis as compare to hemodialysis treatment without β2-m adsorption column [42].
This study also showed improvements of DRA-related symptoms, such as joint pain and
activity of daily living, and it may suggest that the column absorbs not only β2-m, but also
other molecules related to inflammation. Furthermore, a clinical study showed shrink the size
of bone cysts when they are checked by X-ray [43].
4.3. Other kidney replacement therapies
A significant inverse relationship is observed between residual renal function and serum β2-
m level [44]. This suggests that peritoneal dialysis may keep lower serum levels of β2-m because
of better maintenance of intrinsic renal function, but not peritoneal function, than hemodial‐
ysis. However the prevalence of histological DRA in peritoneal dialysis patients is not
significantly different from that observed in a group of hemodialysis patients matched for age
and dialysis duration [23]. End-stage kidney disease patients can do peritoneal dialysis only
for 5-10 years, and it is difficult to discuss which treatment shows benefit to prevent DRA. A
radical approach for DRA is kidney transplantation that reduces serum β2-m, improves
symptoms related to DRA and inhibits the progression [45]. The effects of kidney transplan‐
tation on DRA probably due to not only recover of kidney function but also effect of immu‐
nosuppression therapy.
4.4. Medical and surgical treatment
Use of steroid shows beneficial effect for the pain induced by DRA while surgical treatment
will be needed for advanced CTS and DSA. However, DSA induces serious neurological
symptoms and it is sometimes hard to relief them with surgery. For example, 95 of 865 patients
undergoing dialysis treatment had surgeries for DSA, while rate of post-operative complica‐
tions, such as infection and cardiac events, was much higher than those without DSA [46].
5. DRA, a part of chronic kidney disease-mineral and bone disorder
Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a systemic disorder, which
consists from abnormal levels of mineral-related bicochemistries, bone abnormalities, and soft
tissue calcification [47]. Various types of bone abnormalities are observed in CKD patients,
such as high-turnover bone disease and osteomalacia. DRA causes bone abnormalities in
patients undergoing dialysis treatment. Bone cyst, joint arthropathy, and DSA are frequency
and specifically found in patients especially undergoing long-term hemodialysis therapy [48].
It remains controversial whether DRA and related osteopathy should be included in CKD-
MBD. However, DRA is at least closely involved with CKD-MBD, from the view point of
preventing osteoarticular complications in dialysis patients (Figure 6).
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Figure 6. Dialysis-related amyloidosis (DRA) in chronic kidney disease-mineral bone disorder (CKD-MBD). CKD-MBD as
well as DRA contains various types of bone abnormalities. Furthermore, β2-microglobulin/DRA may be involved with
cardiovascular disease, bone fracture, and mortality which are clinical outcomes of CKD-MBD. In the view point of
bone abnormalities, DRA may be related strongly with CKD-MBD.
CKD- MBD contains various types of bone abnormalities, such as high-turnover bone disease,
osteomalacia, and adyanmic bone disease. DRA, such as bone cyst, joint arthropathy and DSA,
also causes bone abnormalities and is included in renal osteodystorphy. Recently, some groups
reported the relation between serum levels of β2-m and atherosclerosis [49] or mortality [26],
thus β2-m/DRA may be involved with cardiovascular disease, bone fracture, and mortality
which are clinical outcomes of CKD-MBD. In the view point of bone abnormalities, DRA
related osteopathy may enhance the serious bone disorder, such as bone fractures and DSA,
in the presence of other bone abnormalities, such as high-turnover bone disease and osteo‐
malacia. DRA is a serious complication in patients who are receiving long-term dialysis
therapy and obviously seems more harmful than other osteodystrophy in terms of mainte‐
nance of their ADL and quality of life. Further studies will be needed for this assumption.
6. Conclusion
DRA is still one of major and serious complications in end-stage kidney disease patients
undergoing long-term dialysis treatment. Several biomolecules that may relate to Aβ2M
amyloidogenesis are raised from in vitro studies, and that will be needed to investigate the
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involvement in amyloid deposition in vivo. These findings will develop more beneficial
prevention and treatment for DRA as well as improvement of dialysis treatment.
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